Dyne Therapeutics posts widened Q3 2026 loss as R&D spending climbs
Dyne Therapeutics reported a net loss of $193.6 million for the third quarter of 2026, compared with $108.0 million a year earlier. Research and development expenses increased to $161.7 million, while general and administrative costs rose to $35.3 million. The company held $1.134 billion in cash, cash equivalents and marketable securities at September 30 2026, which it says will fund operations into the second quarter of 2028. FDA priority review of the z‑rostudirsen BLA targets a decision by January 21 2027, and topline data from the ACHIEVE trial are expected in the first quarter of 2027.
Why it matters
The larger loss reflects higher spending on drug development, which may pressure the share price in the short term. The cash runway through Q2 2028 gives the company time to pursue regulatory approvals and potential product launches, reducing immediate financing risk.
Key facts
- 1Net loss for Q3 2026 was $193.6 million, or $1.06 per share. tradingview.com
- 2Net loss for Q3 2025 was $108.0 million, or $0.76 per share. tradingview.com
- 3Research and development expenses were $161.7 million, up from $97.2 million in Q3 2025. tradingview.com
- 4General and administrative expenses were $35.3 million, up from $16.7 million in Q3 2025. tradingview.com
- 5Cash, cash equivalents and marketable securities totaled $1.134 billion as of September 30 2026. tradingview.com
- 6The cash balance is expected to fund operations into the second quarter of 2028. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.